Switching among oral anticoagulants: is it logical?

Curr Med Res Opin

Department of Cardiology, Faculty of Medicine, Mugla Sitki Kocman University, Muğla, Turkey.

Published: February 2020

Download full-text PDF

Source
http://dx.doi.org/10.1080/03007995.2019.1662196DOI Listing

Publication Analysis

Top Keywords

switching oral
4
oral anticoagulants
4
anticoagulants logical?
4
switching
1
anticoagulants
1
logical?
1

Similar Publications

Lip ulcers associated with endotracheal tube fixation are a known complication in adults, but their prevalence in neonates and preterm infants remains unclear. We report a case of a right oral commissure ulcer that developed during endotracheal tube fixation at the right oral commissure and left lateral decubitus positioning in an extremely preterm infant with unilateral pulmonary interstitial emphysema (PIE). A male infant was born at 24 weeks and four days of gestation, weighing 696 gm.

View Article and Find Full Text PDF

Introduction: Antiretroviral treatment (ART) has significantly enhanced health outcomes for people living with HIV (PLWH). With the evolution of treatment options, there is an increasing interest in the development of long-acting injectable formulations of antiretroviral drugs. These formulations present a promising alternative to oral ART.

View Article and Find Full Text PDF

Soft conductive gels are essential for epidermal electronics but often face challenges when interfacing with uneven surfaces or areas with extensive hair, especially under mechanical stress. In this study, we employed the concept of liquid-to-solid transformation to enhance integration at biointerfaces and designed an in-situ biogel capable of rapidly transitioning between liquid and solid states within 3 min via a temperature switch. The biogel features a semi-interpenetrating polymer network design and dual conduction pathways, resulting in high tensile strength (~1-3 MPa), a skin-compatible modulus (~0.

View Article and Find Full Text PDF

Background: Nusinersen and risdiplam are U.S. Food and Drug Administration (FDA)-approved treatments for spinal muscular atrophy (SMA).

View Article and Find Full Text PDF

FBP1 controls liver cancer evolution from senescent MASH hepatocytes.

Nature

January 2025

Laboratory of Gene Regulation and Signal Transduction, Departments of Pharmacology and Pathology, School of Medicine, University of California San Diego (UCSD), La Jolla, CA, USA.

Hepatocellular carcinoma (HCC) originates from differentiated hepatocytes undergoing compensatory proliferation in livers damaged by viruses or metabolic-dysfunction-associated steatohepatitis (MASH). While increasing HCC risk, MASH triggers p53-dependent hepatocyte senescence, which we found to parallel hypernutrition-induced DNA breaks. How this tumour-suppressive response is bypassed to license oncogenic mutagenesis and enable HCC evolution was previously unclear.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!